ArticleImmunity2025
Sickle cell disease induces chromatin introversion and ferroptosis in CD8
Abstract read
In one paragraph
Article in Immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Renal Medullary Carcinoma: Utility of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Ferroptosis in colorectal cancer: Molecular mechanisms and regulatory crosstalk with therapeutic prospects (Review).Oncology reports · 2026Review
- Hydrogen Sulfide Rescues Microglia From HIV Tat-Driven Ferroptosis: Implications for HIV-Associated Neuroinflammation.CNS neuroscience & therapeutics · 2026Article
- Translating ferroptosis into oncology: challenges, opportunities and future directions.Nature reviews. Clinical oncology · 2026Review
- Should Sickle Cell Disease Be Considered a Cancer Predisposition Syndrome?Children (Basel, Switzerland) · 2026Review
- Decoding the spatiotemporal characteristics of ferroptosis: reshaping tumour therapeutic strategies.Experimental hematology & oncology · 2026Review
- Targeting TRIM25 as a therapeutic strategy to enhance ferroptosis in glioblastoma cells.Journal of nanobiotechnology · 2026Article
- Reactive sulfur species as emerging immunomodulators: mechanistic insights and therapeutic prospects.Frontiers in immunology · 2026Review
- Programmed Cell Death in Urological Cancers: Orchestrating the Immune Microenvironment and Immunotherapy.Oncology research · 2026Review
- The Janus face of tissue-resident memory T cells: dual programming in tumor immune surveillance and autoimmune pathology.Frontiers in immunology · 2026Review
- When Blood Disorders Meet Cancer: Uncovering the Oncogenic Landscape of Sickle Cell Disease.Journal of clinical medicine · 2025Review
- Ferroptosis in the tumor microenvironment: mechanisms, advances, and therapeutic perspectives.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Zilong ZhaoDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Benxia HuDepartment of Biochemistry and Molecular Biology, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA.
Yalan DengDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Melinda SoeungDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jun YaoDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Lanxin BeiDepartment of Biochemistry and Molecular Biology, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA.
Yaohua ZhangDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Pengju GongDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Lisa A HuangDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Zhou JiangDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jian GaoDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Shuang PengDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Tina K NguyenDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Menuka KarkiDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Bora LimDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cassian YeeDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jared K BurksDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Qing ZhangSimmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Li MaDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate School of Biomedical Sciences, University of Texas MD Anderson Cancer Center and UTHealth, Houston, TX 77030, USA.
Jianjun GaoDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Nizar M TannirDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Leng HanDepartment of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Dihua YuDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate School of Biomedical Sciences, University of Texas MD Anderson Cancer Center and UTHealth, Houston, TX 77030, USA.
Linghua WangGraduate School of Biomedical Sciences, University of Texas MD Anderson Cancer Center and UTHealth, Houston, TX 77030, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; The James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Institute for Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Michael A CurranDepartment of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Maria A GubbiottiDepartment of Anatomic Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Giannicola GenoveseDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Boyi GanDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate School of Biomedical Sciences, University of Texas MD Anderson Cancer Center and UTHealth, Houston, TX 77030, USA.
Wenbo LiDepartment of Biochemistry and Molecular Biology, McGovern Medical School, University of Texas Health Science Center, Houston, TX 77030, USA; Graduate School of Biomedical Sciences, University of Texas MD Anderson Cancer Center and UTHealth, Houston, TX 77030, USA; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, TX 77030, USA. Electronic address: wenbo.li@uth.tmc.edu.
Pavlos MsaouelDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: pmsaouel@mdanderson.org.
Liuqing YangDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate School of Biomedical Sciences, University of Texas MD Anderson Cancer Center and UTHealth, Houston, TX 77030, USA. Electronic address: lyang7@mdanderson.org.
Chunru LinDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate School of Biomedical Sciences, University of Texas MD Anderson Cancer Center and UTHealth, Houston, TX 77030, USA. Electronic address: clin2@mdanderson.org.
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8MTumor hypoxia promotes acquired resistance to radiation through ferroptosis inhibitionU54CA274220 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI David Piwnica-Worms · 2022 to 2026
$8.4MBeyond Gene Dosage: Understanding Down Syndrome via 4D Genome OrganizationU01HL156059 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LI, WENBO · 2020 to 2024
$3.1MEnhancer RNAs in brain gene regulation and Alzheimer's diseaseR01AG082132 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Wenbo Li · 2023 to 2026
$3.0MLong Noncoding RNA Advocates Immune Resistant MicroenvironmentR01CA231011 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIN, CHUNRU · 2019 to 2023
$2.9MDecoding tumor metabolic and immunologic interactions driving racial disparity in African American patients with bladder cancer.R01CA282282 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Jianjun Gao, Nagireddy Putluri · 2023 to 2026
$2.5MTargeting SLC7A11-induced nutrient dependency in cancer: mechanisms and preclinical translationR01CA244144 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GAN, BOYI · 2020 to 2024
$2.1MElucidating T Cell Ferroptosis in Renal Medullary Carcinoma: 3D Genome Architecture Rewiring and Therapeutic AlleviationR01CA285454 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Wenbo Li, Pavlos Msaouel · 2024 to 2026
$2.0MMechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal MalignanciesR37CA288448 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Pavlos Msaouel · 2024 to 2026
$2.0MMechanisms Underlying Enhancer Rnp Mediated Gene Regulation And Genome OrganizationR01GM136922 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LI, WENBO · 2020 to 2024
$2.0MMolecular Mechanisms of Bladder Cancer ImmunometabolismR01CA269489 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Jianjun Gao, Liuqing Yang · 2023 to 2026
$2.0MTargeting ferroptosis in cancer therapyR01CA269646 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Boyi Gan · 2023 to 2026
$2.0MNCI NIH HHS P30 CA016672NCI NIH HHS R01 CA218025NCI NIH HHS R01 CA218036NCI NIH HHS R01 CA231011NCI NIH HHS R01 CA244144NCI NIH HHS R01 CA247992NCI NIH HHS R01 CA269489NCI NIH HHS R01 CA269646NCI NIH HHS R01 CA282282NCI NIH HHS R01 CA285454NCI NIH HHS R37 CA288448NCI NIH HHS U54 CA274220NHLBI NIH HHS U01 HL156059NIA NIH HHS R01 AG082132NICHD NIH HHS R01 HD110520NIGMS NIH HHS R01 GM136922
Abstract
Understanding how genetic disorders affect CD8
Indexed as
Anemia, Sickle CellCD8-Positive T-LymphocytesChromatinFerroptosisNeoplasmsAmino Acid Transport System y+AnimalsDisease Models, AnimalHumansMiceMice, Inbred C57BLTumor MicroenvironmentAmino Acid Transport System y+ChromatinCD8(+) T cellsferroptosisgenomic architecture alterationH(2)SHi-Cimmune checkpoint inhibitorsrenal medullary carcinomasickle cell diseaseSLC7A11SMARCB1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.